Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dalton Trans. 2007 Nov 21;(43):4903-17. Epub 2007 Sep 19.

Metal based drugs: from serendipity to design.

Author information

  • AnorMED, Canada. simonfricker@shaw.ca

Abstract

The platinum anticancer drug cisplatin has made a major contribution to the treatment of testicular and ovarian cancer. This chance discovery has been the stimulus for research into other metal-based drugs. Inorganic chemistry offers many opportunities for medicinal chemistry, and the discovery of metal-based drugs has moved on from chance discovery to rational drug design. There are however, many challenges associated with the drug discovery and development process. The aim of this review is to provide case histories exemplifying the role of rational drug design in modern inorganic medicinal chemistry in the context of these challenges. The evolution of platinum drugs from cisplatin to third generation drugs is described. The molecular target for the platinum agents is DNA. Alternative molecular targets such as thiol-containing proteins and redox processes are proposed. The example of a simple, safe, efficacious metal-based drug, Fosrenol, is reviewed.

PMID:
17992275
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Royal Society of Chemistry
    Loading ...
    Write to the Help Desk